Evidence map›Paper›PMID 40462959›Full record

ArticlebioRxiv : the preprint server for biology2025

Mechanoimmunological Control of Metastatic Site Selection.

Yassmin A Elbanna, Maria Tello-Lafoz, Aliya Holland, Ye Zhang, Jun-Goo Kwak, Zhenghan Wang, Alexandrina Yakimov, Myra Dada, Samuel Vayner, Sarah M Duquette and 9 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Yassmin A ElbannaLouis V. Gerstner, Jr., Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY USA.
Maria Tello-LafozImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY USA.
Aliya HollandPharmacology Program, Weill Cornell Graduate School of Medical Sciences, New York, NY USA.
Ye ZhangKoch Institute for Integrative Cancer Research and Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA USA.
Jun-Goo KwakDepartment of Chemical Engineering, Institute for Applied Life Sciences, University of Massachusetts, Amherst, MA USA.
Zhenghan WangCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY USA.
Alexandrina YakimovImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY USA.
Myra DadaKoch Institute for Integrative Cancer Research and Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA USA.
Samuel VaynerKoch Institute for Integrative Cancer Research and Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA USA.
Sarah M DuquetteKoch Institute for Integrative Cancer Research and Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA USA.
Young Hun KimMolecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY USA.
Tejus A BaleDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY USA.
Benjamin Y WinerImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY USA.
Kenny K H YuDepartment of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY USA.
Joan MassaguéCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY USA.
Jungwoo LeeDepartment of Chemical Engineering, Institute for Applied Life Sciences, University of Massachusetts, Amherst, MA USA.
Ori BarzilaiDepartment of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY USA.
Scott R ManalisKoch Institute for Integrative Cancer Research and Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA USA.
Morgan HuseImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Paula T Hammond · 1985 to 2026
$93.9M
The TGF Beta Signaling Pathway in Development and CancerR35CA252978 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI JOAN MASSAGUE · 2020 to 2026
$7.3M
Synaptic Control of Cytotoxic T cell FunctionR01AI087644 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI HUSE, MORGAN A · 2010 to 2025
$7.3M
A Mechanoimmunological Basis for Metastatic Site PreferenceR01CA286566 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Morgan A Huse · 2024 to 2026
$2.8M
Implantable pre-metastatic niche to elucidate the impact of chemotherapy-induced metastatic relapseR01CA237171 · NCI · UNIVERSITY OF MASSACHUSETTS AMHERST · PI LEE, JUNGWOO · 2019 to 2023
$1.8M
A Mechanoimmunological Basis for Metastatic Site PreferenceF31CA294974 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Yassmin A Laymoun · 2024 to 2026
$149k
NCI NIH HHS F31 CA294974NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA014051NCI NIH HHS R01 CA237171NCI NIH HHS R01 CA286566NCI NIH HHS R35 CA252978NIAID NIH HHS R01 AI087644
6 · The paper itself

Abstract

Cancer cells alter their mechanical properties in response to the rigidity of their environment. Here, we explored the implications of this environmental mechanosensing for anti-tumor immunosurveillance using single cell biophysical profiling and metastasis models. Cancer cells stiffened in more rigid environments, a biophysical change that sensitized them to cytotoxic lymphocytes. In immunodeficient mice, this behavior manifested in the outgrowth of stiffer metastatic cells in the rigid bone than in the soft lung, while in immunocompetent hosts, it led to preferential elimination of stiffer cancer cells and suppression of bone metastasis. Environmentally-induced cell stiffening and immune sensitization both required Osteopontin, a secreted glycoprotein that is upregulated during bone colonization. Analysis of patient metastases spanning mechanically distinct tissues revealed associations between environmental rigidity, immune infiltration, and cancer cell stiffness consistent with mechanically driven immunosurveillance. These results demonstrate how environmental mechanosensing modulates anti-tumor immunity and suggest a mechanoimmunological basis for metastatic site selection.

Identifiers

PMID40462959
PMCPMC12132180

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.